NanoViricides Awaits Regulatory Approval To Begin Phase II Clinical Trial Of NV-387 Oral Gummies As Treatment For Current Bundibugyo Ebolavirus In Democratic Republic Of Congo

Loading news article.

NanoViricides Awaits Regulatory Approval To Begin Phase II Clinical Trial Of NV-387 Oral Gummies As Treatment For Current Bundibugyo Ebolavirus In Democratic Republic Of Congo | WAPE

NanoViricides Awaits Regulatory Approval To Begin Phase II Clinical Trial Of NV-387 Oral Gummies As Treatment For Current Bundibugyo Ebolavirus In Democratic Republic Of Congo

Article summary

Related companies

Comments —